BioSpace News Archive

Drug Development

Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH

Overall response rate (ORR) of 61% and complete response (CR) rate of 28% in 74 patients with indolent non-Hodgkin’s lymphoma (iNHL)

December 2, 2018
·
8 min read
Drug Development

Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting

Maintenance Therapy with NINLARO™ (ixazomib) Improved Progression-Free Survival in Adult Patients with Multiple Myeloma Following Autologous Stem Cell Transplant

December 2, 2018
·
13 min read
Drug Development

Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2 Clinical Trials in B cell Malignancies at the 60th ASH Annual Meeting

Initial results were presented from ongoing Phase 1/2 trials in pediatric acute lymphoblastic leukemia (AMELIA trial) and diffuse B cell lymphoma (ALEXANDER trial)

December 2, 2018
·
8 min read
Drug Development

MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting

Data Support Complementary Potential of Intermittent and Continuous Dosing Schedules as Means to Optimize Clinical Risk-Benefit Ratio in Relapsed/Refractory Follicular Lymphoma Patients

December 2, 2018
·
8 min read
Drug Development

Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego

95% ORR (by IWG) in 20 evaluable patients

December 2, 2018
·
5 min read
Drug Development

Harpoon Therapeutics Presents Preclinical Data Supporting Development of HPN217, a New BCMA-Targeting TriTAC, at the 2018 American Society of Hematology (ASH) Annual Meeting

Harpoon’s Third Product Candidate is Slated for Clinical Development in 2019

December 2, 2018
·
3 min read
Drug Development

Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R2) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018

Pivotal phase 3 data show investigational R2 significantly extended progression-free survival compared with rituximab plus placebo

December 2, 2018
·
18 min read
Drug Development

Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit

Magenta Therapeutics today announced that the Company presented preclinical research on its targeted conditioning programs at the 60th annual meeting of the American Society of Hematology (ASH).

December 2, 2018
·
9 min read
BioForest

Finnish Blood Testing Scale-up and Health Service Provider Introduce Healthcare for the 21st Century - Connecting Molecular Medicine With Lifestyle Habits

The new service, Virta 360, connects a person’s current state of physical health with their lifestyle. The service helps people to understand their current risks for chronic diseases and identifies potential areas where they can improve their wellbeing.

December 2, 2018
·
3 min read